Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Monte Rosa Therapeutics Inc (NQ: GLUE )

4.620 +0.050 (+1.09%)
Streaming Delayed Price Updated: 9:47 AM EDT, Jul 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces Leadership Team Promotions
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory Board 
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.